Vivos Therapeutics Income Statement (2019-2026) | VVOS

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
4.50M4.55M4.39M3.64M4.18M4.25M3.95M3.86M3.40M3.30M3.25M3.42M4.05M3.86M3.70M3.02M3.82M6.78M3.82M5.14M
Cost of Revenue (Quarter)
0.87M1.36M1.29M1.09M1.60M1.75M1.57M1.52M1.30M1.55M1.16M1.48M1.40M1.53M1.60M1.51M1.71M2.85M0.84M2.08M
Gross Profit (Quarter)
3.62M3.18M3.11M2.55M2.59M2.50M2.38M2.34M2.10M1.75M2.09M1.94M2.65M2.33M2.10M1.51M2.11M3.94M2.99M3.06M
Operating items
Research & Development (Quarter)
1.40M1.98M1.32M0.75M1.70M1.11M1.35M0.63M0.59M0.64M0.61M0.66M0.32M0.35M0.41M0.36M0.26M0.40M0.38M0.25M
Selling, General & Administrative (Quarter)
6.09M6.52M8.12M8.28M7.69M6.62M6.92M6.54M5.88M4.60M5.47M4.92M4.12M4.49M4.35M4.89M6.41M7.88M8.55M8.97M
Other Operating Expenses (Quarter)
0.20M0.19M1.08M0.16M0.16M0.17M0.17M0.17M0.15M0.15M0.15M0.15M0.14M0.15M0.14M0.18M0.31M0.38M0.44M0.45M
Operating Expenses (Quarter)
7.68M8.69M10.52M9.19M9.55M7.90M8.45M7.34M6.62M5.39M6.22M5.72M4.59M4.98M4.90M5.43M6.97M8.67M9.37M9.67M
Operating Income (Quarter)
-4.06M-5.50M-7.41M-6.64M-6.96M-5.41M-6.06M-5.00M-4.52M-3.64M-4.13M-3.79M-1.94M-2.65M-2.81M-3.92M-4.87M-4.73M-6.38M-6.62M
EBIT (Quarter)
-4.06M-5.50M-7.41M-6.64M-6.96M-5.41M-6.06M-5.00M-4.52M-3.64M-4.13M-3.79M-1.94M-2.65M-2.81M-3.92M-4.87M-4.73M-6.38M-6.62M
Non-operating items
Other Non Operating Income (Quarter)
0.02M0.06M-0.10M-0.04M-0.04M-0.04M-0.04M0.05M-0.23M-0.05M-0.01M-0.00M-0.02M-0.02M-0.07M-0.00M-0.16M-0.68M-0.63M-1.17M
Net income details
EBT (Quarter)
-4.04M-5.45M-7.41M-5.33M-6.99M-5.43M-6.19M-1.70M-5.53M-2.09M9.37M-3.76M-1.93M-2.62M-2.88M-3.86M-5.01M-5.40M-6.95M-7.75M
Profit After Tax (Quarter)
-4.04M-5.45M-7.39M-5.33M-6.99M-5.43M-6.00M-1.70M-5.53M-2.09M-4.30M-3.76M-1.93M-2.60M-2.84M-3.90M-5.01M-5.40M-6.92M-7.75M
Income from Non-Controlling Interests (Quarter)
-0.07M
Income from Continuing Operations (Quarter)
-4.04M-5.45M-7.41M-5.33M-6.99M-5.43M-6.19M-1.70M-5.53M-2.09M9.37M-3.76M-1.93M-2.62M-2.88M-3.86M-5.01M-5.40M-6.95M-7.75M
Consolidated Net Income (Quarter)
-4.04M-5.45M-7.41M-5.33M-6.99M-5.43M-6.19M-1.70M-5.53M-2.09M9.37M-3.76M-1.93M-2.62M-2.88M-3.86M-5.01M-5.40M-6.95M-7.75M
Income towards Parent Company (Quarter)
-4.04M-5.45M-7.41M-5.33M-6.99M-5.43M-6.19M-1.70M-5.53M-2.09M9.37M-3.76M-1.93M-2.62M-2.88M-3.86M-5.01M-5.40M-6.95M-7.75M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-4.04M-5.45M-7.39M-5.33M-6.99M-5.43M-6.09M-1.70M-5.53M-2.09M9.37M-3.76M-1.93M-2.62M-2.88M-3.86M-5.01M-5.40M-6.95M-7.68M
Additional items
EPS (Basic) (Quarter)
-4.87-6.55-8.70-6.28-0.01-0.01-0.01-1.72-4.62-1.757.68-1.63-0.60-0.40-0.57-0.45-0.55-0.49-0.68-0.52
EPS (Diluted) (Quarter)
-8.23-6.40-6.61-1.72-4.62-1.757.68-1.63-0.60-0.40-0.57-0.45-0.55-0.49-0.68-0.52
Shares Outstanding (Quarter)
0.83M0.83M0.85M0.85M849.34M849.34M920.48M0.99M1.20M1.20M1.22M2.31M3.23M6.62M5.02M8.60M9.09M10.96M10.27M14.63M
Shares Outstanding (Diluted) (Quarter)
0.85M0.85M0.92M0.99M1.20M1.20M1.22M2.31M3.23M6.62M5.02M8.60M9.09M10.96M10.27M14.63M
Shares Outstanding (Entity) (Quarter)
0.91M0.92M0.92M0.92M849.34M849.34M920.48M0.99M1.20M1.20M1.22M2.73M3.40M6.62M5.89M8.60M7.32M10.96M9.29M
EBITDA (Quarter)
-4.06M-5.50M-7.41M-6.64M-6.96M-5.41M-6.06M-5.00M-4.52M-3.64M-4.13M-3.79M-1.94M-2.65M-2.81M-3.92M-4.87M-4.73M-6.38M-6.62M
Interest Expenses (Quarter)
1.14M1.95M0.00M0.10M0.69M0.65M0.44M0.49M2.66M2.51M0.65M2.20M0.49M0.03M0.00M0.03M-0.72M-0.34M0.80M-1.38M